Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8791085 | American Journal of Ophthalmology Case Reports | 2018 | 6 Pages |
Abstract
These two patients with MPS I receiving Laronidase treatment have developed bull's eye maculopathy changes and subfoveal deposition of hyperreflectant material despite excellent compliance and good tolerance of the standard dose of enzyme therapy for this disorder. Further studies are required to determine the nature of the material, the incidence and the effect of enzyme replacement therapy on these findings in patients with MPS I.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Heather G. Mack, R.C. Andrew Symons, Gerard de Jong,